Europe Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-base

Europe Influenza Vaccines Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Vaccine Type (Quadrivalent Vaccines and Trivalent Vaccines), Virus Type (Influenza Virus Type A and Influenza Virus Type B), Technology (Egg-based and Cell-based), Route of Administration (Injection and Nasal Spray), and Target Group (Infants, Children, Adults, and Elderly People)

The influenza vaccines market in Europe is expected to grow from US$ 2,261.85 million in 2022 to US$ 3,424.02 million by 2028; it is estimated to grow at a CAGR of 7.2% from 2022 to 2028.

Increasing Investment by Top Market Players and Governments Boosts Europe Influenza Vaccines Market

Market players and governments worldwide are increasing their investments in vaccine development and immunization. For instance, in March 2021, Sanofi (Paris, France) announced an approximately US$ 925 million investment in a new vaccine manufacturing plant at its pre-existing site in Toronto, Canada. Investments in the new facility will provide additional antigen and filling capacity for Sanofi's FLUZONE high-dose quadrivalent influenza vaccines, increasing availability in Canada, the US, and Europe in the coming years. In April 2021, 3 levels of government—federal, provincial, and municipal—supported Sanofi Pasteur in building an end-to-end influenza vaccines factory in Toronto. The partners will invest ~US$ 1 billion to get the site up and running by 2027. Sanofi, for its part, will invest more than US$ 55 million, create 165 new eligible jobs, and maintain another 1,100. In addition, Sanofi will also invest ~US$ 79 million annually for 8 years to fund research and development in Canada.

In June 2021, The European Investment Bank signed a US$ 30.55 million global vaccine distribution agreement with biotech company Univercells to mass produce the COVID-19 vaccine at a new Belgian site. It helped build other vaccine factories across the world. In April 2022, the bank provided a US$ 15.27 million loan to IRBM, an Italian biomedical research company, to expand its vaccine production capacity and strengthen research on COVID-19 and other diseases. Thus, the increase in investment by top market players and governments across the region is bolstering the Europe influenza vaccines market.

Market Overview

Europe accounted for the second largest market owing to factors such as the rising geriatric population, increasing prevalence of flu and related illness, and growing demand for the development of new vaccines in the region. In addition, growing funding for research & development activities is likely to provide more opportunities in the coming years across the region.

Europe Influenza Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Europe Influenza Vaccines Market Segmentation

The Europe influenza vaccines market is segmented on the basis of vaccine type, virus type, technology, route of administration, target group, and country.

Based on vaccine type, the Europe influenza vaccines market is bifurcated into quadrivalent vaccines and trivalent vaccines. The quadrivalent vaccines segment registered a larger share of the market in 2022.

Based on virus type, the Europe influenza vaccines market is bifurcated into influenza virus type A and influenza virus type B. The influenza virus type A segment held a larger share of the market in 2022.

Based on technology, the Europe influenza vaccines market is divided into egg-based and cell-based. The egg-based segment held a larger share of the market in 2022.

Based on route of administration, the Europe influenza vaccines market is divided into injection and nasal spray. The injection segment held a larger share of the market in 2022.

Based on target group, the Europe influenza vaccines market is segmented into infants, children, adults, and elderly people. The infants segment held the largest share of the market in 2022.

Based on country, the Europe influenza vaccines market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK dominated the market in 2022.

AstraZeneca; Emergent BioSolutions Inc.; GlaxoSmithKline plc.; Mitsubishi Chemical Group Corporation; Moderna, Inc.; MYLAN N.V.; Sanofi; SEQIRUS; and Serum Institute of India Pvt. Ltd are the leading companies operating in the influenza vaccines market in Europe.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe Influenza Vaccines Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Europe Influenza Vaccines Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution